Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054808 · ClinicalTrials.gov registry record · Phase 2
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00054808 is a Phase 2 study that has completed, run by Genta Incorporated. The registered enrollment target is 40 participants.
The verdict
NCT00054808, a Phase 2 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.
Interventions
- DRUG gallium nitrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054808
The ClinicalTrials.gov registry entry for NCT00054808 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genta Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gallium nitrate is the first listed.
NCT00054808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054808 about?
NCT00054808 is a clinical study titled "Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma". Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. S...
What is the current status of trial NCT00054808?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-06.
What interventions are being tested in trial NCT00054808?
The interventions under investigation include: gallium nitrate (DRUG).
Who is sponsoring clinical trial NCT00054808?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.